The Lustgarten Equity, Accessibility, and Diversity (LEAD) Project funds institutional programs that increase recruitment and retention of under‑represented groups in pancreatic cancer clinical trials. The program targets structural, communication, and logistical barriers to participation, with measurable goals for equity in trial access. Projects must demonstrate clear, trackable impact on diversity in pancreatic cancer research.
Eligibility Criteria:
- Cancer centers or institutions conducting pancreatic cancer clinical trials with substantial pancreatic cancer patient volume.
- Programs must specifically address recruitment and retention of under‑represented minority patients in pancreatic cancer trials.
- Institutions must be able to meet Lustgarten’s financial, ethical, and reporting requirements.
- Open internationally for eligible institutions as defined in the RFA.
Funding Details:
- Programmatic grants supporting institutional or multi‑institution initiatives.
- Historically up to approximately USD 150,000 per year for up to 3 years, including limited indirect costs (exact budget per current RFA).
- Funds may support staff, outreach, navigation, data collection, and other trial equity activities.
Deadline:
- Current cycle application deadline: January 5, 2026.
- Funding start: Mid‑2026 (per award agreement).
Where to go for further information: